KCNH2 and Familial short QT syndrome: The first proof-of-concept hybrid gene therapy model was demonstrated for KCNQ1- and KCNH2-mediated LQTS and SQTS using short hairpin RNAs in a dual-component SupRep method, which silenced the mutant allele and replaced it with WT expression (71, 72).